Prostate cancer (PC), the second most common male cancer, affects 1.3 mil men and accounts for +360,000 deaths annually worldwide. At an early stage, local treatments (i.e. surgery, chemical castration and chemotherapy) often cure PC initially. However, an estimated 10-30% progress to metastatic castration-resistant PC (mCRPC) with no curative options, and 70% of patients with mCRPC die within 5 years. This highlights the need for more effective treatments such as immunotherapy with check point inhibitors that has shown remarkable clinical success with other cancer types but minimal efficacy in mCRPC due to the immunologically non-inflammatory nature of PC, characterised by restricted immune cell infiltration. Our approach addresses this unmet need through a bispecific monoclonal antibody, EBM-001, with specificity to Prostate-specific Membrane Antigen (PSMA) and IFNy which: 1) captures and accumulates the patient's own circulating IFNy from the blood: followed by 2) their redistribution to the site of the tumor, igniting an immunological activation by attracting the patient's immune cells to the cancer site. The unique mode of action of EBM-001, will enable a safe long lasting immune infiltration that will improve the efficacy of current immunotherapies for mCRPC. Our consortium (Ebumab, Southern University of Denmark, Bioneer) will use this Grand Solutions project to advance EBM-001 from the current initial proof of concept, to provide in vivo PoC and CMC development.

(af forretningsmæssige årsager er vi ikke interesseret i for meget offentlighed endnu)